Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies
PW Wolstencroft, DF Fiorentino - Current rheumatology reports, 2018 - Springer
PW Wolstencroft, DF Fiorentino
Current rheumatology reports, 2018•SpringerPurpose of review Dermatomyositis is an idiopathic inflammatory myopathy with a variety of
systemic and cutaneous manifestations. The myositis-specific autoantibodies (MSAs) are
associated with phenotypic features and provide a tool for sub-classification of
dermatomyositis patients. This review focuses on recent work characterizing the clinical
features that accompany the MSAs in dermatomyositis. Recent findings There is increasing
recognition of the distinct clinical and pathological phenotypes associated with each MSA …
systemic and cutaneous manifestations. The myositis-specific autoantibodies (MSAs) are
associated with phenotypic features and provide a tool for sub-classification of
dermatomyositis patients. This review focuses on recent work characterizing the clinical
features that accompany the MSAs in dermatomyositis. Recent findings There is increasing
recognition of the distinct clinical and pathological phenotypes associated with each MSA …
Purpose of review
Dermatomyositis is an idiopathic inflammatory myopathy with a variety of systemic and cutaneous manifestations. The myositis-specific autoantibodies (MSAs) are associated with phenotypic features and provide a tool for sub-classification of dermatomyositis patients. This review focuses on recent work characterizing the clinical features that accompany the MSAs in dermatomyositis.
Recent findings
There is increasing recognition of the distinct clinical and pathological phenotypes associated with each MSA. Most of these features display considerable overlap between MSA groups. Despite this, there are notable differences between the typical combinations of cutaneous and systemic manifestations, response to therapy, prognosis, and disease sequelae that define each dermatomyositis MSA group.
Summary
The MSAs may ultimately improve diagnosis and sub-classification of dermatomyositis patients. However, more work is needed to understand the pathologic basis for much of the heterogeneity found within these subgroups.
Springer